ARTICLE | Clinical News
Subcutaneous Cinryze: Phase II data
January 9, 2012 8:00 AM UTC
Top-line data from an open-label Phase II trial in 12 patients with HAE showed that twice-weekly 1,000 and 2,000 U doses of subcutaneous Cinryze formulated with rHuPH20 led to higher maximum levels a...